~ Buy the DUOBRII (halobetasol propionate; tazarotene) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR DUOBRII

All Clinical Trials for duobrii

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04119102 ↗	Duobrii in Combination With Biologics	Recruiting	Ortho Dermatologics	Phase 4	2019-10-14	12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
NCT04119102 ↗	Duobrii in Combination With Biologics	Recruiting	Psoriasis Treatment Center of Central New Jersey	Phase 4	2019-10-14	12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
NCT04720105 ↗	Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis	Recruiting	Bausch Health Americas, Inc.	Phase 4	2020-11-19	The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.
NCT04720105 ↗	Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis	Recruiting	Icahn School of Medicine at Mount Sinai	Phase 4	2020-11-19	The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.
NCT05203315 ↗	Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults	Not yet recruiting	OrthoDermatologics	Phase 3	2022-01-17	This study seeks to evaluate the safety, tolerability, and efficacy of topical Duobrii® Lotion in adult subjects with mild plaque psoriasis.
NCT05203315 ↗	Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults	Not yet recruiting	Austin Institute for Clinical Research	Phase 3	2022-01-17	This study seeks to evaluate the safety, tolerability, and efficacy of topical Duobrii® Lotion in adult subjects with mild plaque psoriasis.
NCT05282771 ↗	A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.	Completed	Taro Pharmaceuticals USA	Early Phase 1	2021-04-16	To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psoriasis.

Clinical Trial Conditions for duobrii

Condition Name

Condition Name for duobrii
Intervention	Trials
Plaque Psoriasis	3
Acne Keloidalis Nuchae	1
AKN	1
Palmoplantar Psoriasis	1

Condition MeSH

Condition MeSH for duobrii
Intervention	Trials
Psoriasis	5
Acne Keloid	1

Clinical Trial Locations for duobrii

Trials by Country

Trials by Country for duobrii
Location	Trials
United States	5

Trials by US State

Trials by US State for duobrii
Location	Trials
North Carolina	2
New York	2
New Jersey	1

Clinical Trial Progress for duobrii

Clinical Trial Phase

Clinical Trial Phase for duobrii
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	2
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for duobrii
Clinical Trial Phase	Trials
Recruiting	4
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for duobrii

Sponsor Name

Sponsor Name for duobrii
Sponsor	Trials
Bausch Health Americas, Inc.	2
Icahn School of Medicine at Mount Sinai	2
Ortho Dermatologics	2

Sponsor Type

Sponsor Type for duobrii
Sponsor	Trials
Other	6
Industry	5